IMMUNOME IS FOCUSED ON DEVELOPING FIRST-IN-CLASS THERAPEUTICS DESIGNED TO CHANGE THE WAY WE UNDERSTAND AND TREAT DISEASE
Immunome was founded to advance the discovery and development of novel antibody-based drugs. Our proprietary antibody discovery platform identifies novel therapeutic antibodies, and their targets, by leveraging the most highly-educated components of the B cells from patients who have learned to fight off their disease.
Speed, efficiency & productivity are the hallmarks of Immunome’s Antibody Discovery Engine. By directly interrogating human B cells, we better understand how the body recognizes and overcomes disease. In this way, the Antibody Discovery Engine is able to quickly, accurately and efficiently identify the antibodies with the highest potential to address cancer and infectious diseases. This approach also allows Immunome to circumvent the weaknesses, complications and inefficiencies associated with conventional approaches. We believe that the antibodies we identify, already credentialed by the patient, are ideal for development.
An industrialized technology designed to accelerate drug discovery. Immunome’s single-step technology allows us to move directly from the interrogation of the human B cell to large amounts of antibodies for function-based screening. To date, we have interrogated hundreds of patient samples and produced 200+ hybridoma libraries (>250,000 hybridomas) from patients with various cancers and infectious diseases. With a growing pipeline of novel targets, Immunome is leading the way to create the next generation of antibody therapeutics for cancer and infectious diseases.